arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

TANDEM DIABETES CARE INC

TNDM
$22.38 ▲ +4.45 (+24.86%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
55 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
13
Health
Poor
Bearish
auto_awesome

Analytical Summary

TANDEM DIABETES CARE INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth 5.5%
Op. Margin -7.1%
ROIC -2.4%
FCF / Share $0.07
Trailing P/E
Price / Book 11.6x
FCF Yield 0.3%
Debt / Equity 4.54
info Valuation on last close. End-of-day price, Aug 7, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$247.22M
↑ +5.5%
Net Income Profit after all expenses
$-20.39M
↑ +84.4%
Operating Margin Operating profit as % of sales
-7.1%
↓ -346.9% 11th
FCF / Share Free cash flow per share
$0.07
↑ +13.5%
Long-Term Debt Long-term obligations
$601.77M
↑ +94.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
14
Returns
6
Financial Health
16
Cash Quality
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters